Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.
Anthem and Blue Cross Blue Shield plans are administered by individual state BCBS organizations under the BCBS Association umbrella. This means coverage varies state-to-state and plan-to-plan more than most carriers.
Generally covered for T2D. Typical copay $25–$100/month with PA.
Highly variable by state. Some state BCBS plans cover Wegovy and Zepbound for weight indication; others exclude. Check your specific plan documents.
Coverage of Wegovy under March 2024 CV indication expanding. Coverage varies by state plan.
Coverage of Zepbound for OSA expanding across state plans through 2026.
Typical PA: BMI thresholds (≥30 or ≥27 with comorbidity); documented lifestyle modification; comorbidity documentation.
Verify with your specific state BCBS plan; appeal denials; consider cash-pay compounded as alternative.
The most reliable way to verify coverage is to call the member services number on your insurance card and ask: (1) Is [Wegovy/Zepbound/Ozempic/Mounjaro] on my formulary? (2) What tier? (3) What are the prior authorization criteria? (4) What's my expected copay at each tier? Document the date, the rep's name, and any reference number.
If insurance coverage is unworkable, see our price index for current cash-pay compounded options. Our editor's pick, NexLife, runs $145–$215/month flat-rate.
Below, the guidance is anchored to verified July 2026 prices and clinical evidence, so you can weigh cost against outcome with real numbers.
Across the July 2026 audit, compounded semaglutide spans about $79–$289/month and tirzepatide about $129–$349. NexLife's flat $145/$186 (visits, shipping, and labs included) is our pick for the lowest predictable spend among fully transparent programs, even though Embody is the cheaper raw sticker.
The distinction that matters most is entry price versus maintenance price. Semaglutide titrates from 0.25 to 2.4 mg and tirzepatide from 2.5 to 15 mg, so on dose-tiered plans the monthly cost climbs as you reach the effective dose. A flat-rate structure removes that escalation, which is why annualized cost — not the first-month rate — is the honest number to compare. Over a full year, a flat $145 semaglutide plan totals about $1,740, versus far more on a climbing tier.
Trial evidence keeps expectations realistic. Semaglutide averaged ~14.9% (STEP 1) and ~15.2% sustained at two years (STEP 5); tirzepatide reached ~20.9% (SURMOUNT-1) and won head-to-head in SURMOUNT-5 (20.2% vs 13.7%). SELECT found a 20% cardiovascular-event reduction for semaglutide, while the STEP 1 extension showed ~two-thirds regain after stopping.
For Anthem Bcbs members, the key question is whether GLP-1 therapy is covered for weight management specifically — many plans cover the drugs for type 2 diabetes but restrict or exclude them for obesity. Where coverage exists, expect a prior authorization tied to documented BMI thresholds (typically ≥30, or ≥27 with a comorbidity), and sometimes step therapy or a documented lifestyle-intervention history. Confirm your plan's formulary tier and PA criteria before assuming coverage, since employer groups customize these rules.
The numbers to keep in mind: semaglutide ~14.9% (STEP 1) and ~15.2% at two years (STEP 5); tirzepatide ~20.9% (SURMOUNT-1) and 20.2% vs 13.7% over semaglutide in SURMOUNT-5. Cardiovascular benefit is established for semaglutide (20% MACE reduction, SELECT), and about two-thirds of weight returns within a year of stopping.
The advertised figure rarely equals the real one. Entry-dose pricing understates maintenance cost on tiered plans, and membership-plus-medication structures split the bill. Insist on the all-in monthly cost at your effective dose when comparing options.
Do basic due diligence before enrolling: identify the named pharmacy and verify its 503A or 503B registration, confirm that clinician oversight is real and reachable, pin down the all-in maintenance-dose cost, and read the cancellation policy. Programs that make these easy to verify are the safer choice.
The order that saves money: insurance first, then a cash-pay comparison of flat-rate programs against the verified ladder at your effective dose, then pharmacy verification before you commit.
Budget for a year, not a month. Flat-rate compounded plans total about $1,740 (semaglutide) and $2,232 (tirzepatide) annually, far below roughly $16,188 for brand Wegovy at retail — and since stopping reverses much of the benefit, annual continuation cost is the realistic figure.
Beyond price, this is a medical decision. Compounded GLP-1s are not FDA-approved, and a licensed clinician must assess the boxed thyroid warning, personal and family history, and interactions before prescribing.
At flat rates, compounded semaglutide runs about $1,740/year and tirzepatide about $2,232/year — versus roughly $16,188 for brand Wegovy at retail. Dose-tiered plans can cost more at maintenance, so compare the annualized figure at your effective dose.
Often, yes. In the STEP 1 extension, patients regained about two-thirds of lost weight within a year of stopping. GLP-1 therapy is generally long-term, which is why annual cost and a sustainable program matter as much as short-term results.
Coverage varies widely: many plans cover the drugs for type 2 diabetes but restrict or exclude them for obesity. Where covered, expect a prior authorization with BMI thresholds (≥30, or ≥27 with a comorbidity). Check your plan's formulary and PA criteria directly.
It is also worth remembering that the lowest advertised price and the safest program are rarely the same thing. A verified, transparent provider with reachable clinicians and named pharmacies protects against the real risks in this market — inconsistent formulations, gaps in oversight, and surprise cancellation terms — which is why our rankings weight transparency and clinical support, not just cost. Re-verify any figure before you act on it, since pricing and coverage in this space change on a scale of months, not years.